医药行业周报（2025年第3周）

Investment Rating - The report maintains an "Outperform" rating for the industry [5][28]. Core Insights - The pharmaceutical and biotechnology industry experienced a rebound with a weekly increase of 2.7%, ranking 25th among 31 sectors in the Shenwan classification, outperforming the Shanghai Composite Index and the CSI 300 Index [11][12]. - The weekly trading volume for the pharmaceutical and biotechnology sector reached 245.993 billion yuan [11]. - The chemical pharmaceutical industry had the highest trading volume at 93.918 billion yuan, while the pharmaceutical commercial sector had the lowest at 12.806 billion yuan [16]. - The establishment of the National Molecular Drug Innovation Center aims to enhance drug development for common diseases such as cardiovascular diseases, diabetes, and tumors, utilizing a "company + alliance" model [3][20]. Summary by Sections Industry Overview - The pharmaceutical and biotechnology sector's weekly performance was positive, with all sub-sectors showing gains, particularly the biological products sector, which rose by 3.2% [12][16]. - The highest turnover rate was observed in the chemical pharmaceutical sector at 9.4%, while the biological products sector had the lowest at 4% [16]. Industry News and Important Announcements - The National Healthcare Security Administration held a press conference addressing various topics, including the operation of the medical insurance fund and drug price governance [17]. - The National Medical Products Administration released a draft for public consultation on the revised Medical Device Production Quality Management Standards, aimed at enhancing regulatory oversight [18][19]. - The approval of innovative drugs by various companies, such as the PD-L1 monoclonal antibody by Kelun Pharmaceutical and the approval of the drug Senaparib for ovarian cancer by East China Pharmaceutical, highlights ongoing advancements in the industry [21][22]. Important Announcements - Kelun Pharmaceutical's PD-L1 monoclonal antibody received approval for market launch in China [21]. - East China Pharmaceutical's Senaparib capsule was approved for use in maintaining treatment for ovarian cancer patients [22]. - Renfu Pharmaceutical's carbamazepine sustained-release tablets received FDA approval, marking a significant step in expanding into the U.S. market [23][24].